LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 140

Search options

  1. Article ; Online: Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?

    Dry, Sarah M

    Human pathology

    2024  

    Abstract: Dedifferentiation traditionally is defined by descriptive criteria as a tumor showing an abrupt change in histology from a conventional, classic, low-grade appearing neoplasm to a tumor that is more cellular, pleomorphic and "high grade", with grading ... ...

    Abstract Dedifferentiation traditionally is defined by descriptive criteria as a tumor showing an abrupt change in histology from a conventional, classic, low-grade appearing neoplasm to a tumor that is more cellular, pleomorphic and "high grade", with grading typically being performed by subjective criteria. The dedifferentiated areas range from areas with recognizable histologic differentiation which differs from the primary tumor (such as an osteosarcoma arising from a low-grade chondrosarcoma) to areas containing sarcomas without specific histologic differentiation (such as pleomorphic or spindle cell sarcoma). Many, but not all, dedifferentiated tumors are aggressive and associated with significantly shorter survival than their conventional counterparts, even grade 3 conventional tumors. As a result, dedifferentiated tumors are generally considered to be clinically aggressive and as a result, more aggressive surgery or the addition of (neo)adjuvant chemotherapy is often considered. However, long-term (greater than 20 year) survivors are reported in the most common dedifferentiated bone and soft tissue sarcomas. Moreover, use of mitotic criterion for defining dedifferentiation in dedifferentiated liposarcoma as well as grading (by the French system) have been found to be associated with survival. This paper reviews the literature on dedifferentiated chondrosarcoma, dedifferentiated liposarcoma, dedifferentiated chordoma and dedifferentiated parosteal osteosarcoma. As a result of that review, recommendations are advocated to identify evidence-based, objective diagnostic and grading criteria for dedifferentiation that are appropriate for each tumor type. Adding such criteria will improve consistency in diagnosis worldwide, allow easier comparison of clinical research performed on dedifferentiated tumors and help communicate (to patients and clinicians) the tumors with highest risk of clinically aggressive behavior, to allow appropriate and personalized treatment planning.
    Language English
    Publishing date 2024-02-02
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 207657-3
    ISSN 1532-8392 ; 0046-8177
    ISSN (online) 1532-8392
    ISSN 0046-8177
    DOI 10.1016/j.humpath.2024.02.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Precision Pathology as Part of Precision Medicine: Are We Optimizing Patients' Interests in Prioritizing Use of Limited Tissue Samples?

    McCall, Shannon J / Dry, Sarah M

    JCO precision oncology

    2022  Volume 3, Page(s) 1–6

    Language English
    Publishing date 2022-01-31
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.18.00238
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Rare malignant glomus tumor of the esophagus with pulmonary metastasis: a case report.

    Xiao, Annie / Ahlers, Michael / Dry, Sarah M / Weber, Andrew T / Chiu, Victor Y / Pessegueiro, Antonio M

    AME case reports

    2022  Volume 6, Page(s) 20

    Abstract: Background: Glomus tumors are typically benign soft tissue neoplasms that arise in peripheral cutaneous structures. Visceral organ involvement is exceedingly rare.: Case description: Here we present a case of malignant glomus tumor of the esophagus ... ...

    Abstract Background: Glomus tumors are typically benign soft tissue neoplasms that arise in peripheral cutaneous structures. Visceral organ involvement is exceedingly rare.
    Case description: Here we present a case of malignant glomus tumor of the esophagus with pulmonary metastases in a 57-year-old woman presenting with three weeks of progressive dysphagia, epigastric pain, and 35-pound weight loss. Upper endoscopy revealed a 5×3.5×2.5 cm vascular esophageal mass. Contrast-enhanced CT showed multiple, scattered sub-centimeter pulmonary nodules bilaterally. Diagnosis of metastatic glomus tumor was confirmed immunohistochemically on primary tumor and lung biopsies. Localized resection was not feasible due to the patient's poor condition. A trial of gemcitabine and docetaxel was planned, but the patient experienced rapid clinical deterioration after a single dose of gemcitabine before electing for hospice care.
    Conclusions: We have reviewed the 11 other published cases of esophageal glomus tumors, only one of which was similarly metastatic at time of presentation. Of those patients with localized disease treated with surgical excision, all were alive and had no evidence of recurrence (NER) at their times of publication. In contrast, disease ultimately progressed despite surgery and chemoradiotherapy in the sole other case of metastatic glomus tumor of the esophagus. Although glomus tumors are largely benign entities, this case highlights their rare and aggressive malignant potential.
    Language English
    Publishing date 2022-04-25
    Publishing country China
    Document type Case Reports
    ISSN 2523-1995
    ISSN (online) 2523-1995
    DOI 10.21037/acr-21-72
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Does "Low-Grade" Dedifferentiated Liposarcoma Exist? The Role of Mitotic Index in Separating Dedifferentiated Liposarcoma From Cellular Well-differentiated Liposarcoma.

    Graham, Danielle S / Qorbani, Amir / Eckardt, Mark A / Klingbeil, Kyle D / Chen, Lucia Y / Chopra, Shefali / Eilber, Fritz C / Dry, Sarah M

    The American journal of surgical pathology

    2023  Volume 47, Issue 6, Page(s) 649–660

    Abstract: Background: Subjective, varying criteria identify "low-grade" dedifferentiation in well-differentiated/dedifferentiated liposarcoma (WD/DDLPS). The value of mitotic rate (MR) in defining DDLPS is not confirmed. We studied all patients with the resection ...

    Abstract Background: Subjective, varying criteria identify "low-grade" dedifferentiation in well-differentiated/dedifferentiated liposarcoma (WD/DDLPS). The value of mitotic rate (MR) in defining DDLPS is not confirmed. We studied all patients with the resection of their primary or first recurrence retroperitoneal WD/DDLPS at our institution to determine the value of MR in diagnosing DDLPS and if MR associates with patient survival.
    Design: Ninety-eight patients with retroperitoneal WD/DDLPS operated at our institution from January 1, 1989 to December 31, 2013 were included. Cases were defined as acellular (AC) WDLPS, LS0-4 (tumors with non-lipogenic areas and MR 0-4/10HPFs) or LS5+(non-lipogenic areas, MR≥5/10 HPFs) and graded using the French system. Kaplan-Meier survival estimates with log-rank test and multivariate Cox (mCox) analyses were performed.
    Results: Follow-up was available on all patients (median 9.3 y, range 0.02-23.16 y). Kaplan-Meier demonstrated a significant ( P =0.004) difference in disease-specific survival (DSS) among the 3 groups. mCox demonstrated no difference in DSS between the AC and LS0-4 groups (HR 1.51; 95% CI 0.57-3.99, P =0.412) but significantly lower DSS in the LS5+group compared with the AC group (HR 2.68; 95% CI 1.07-6.71, P =0.035). The difference in DSS was not significant between grade 2 and 3 tumors ( P =0.094). DSS between MR 5-19/10 HPFs and MR20+/10 HPFs subgroups was significant ( P =0.007) but by mCox did not reach significance (HR 2.47; 95% CI 0.96-6.35, P =0.060).
    Conclusion: This study confirms that MR distinguishes DDLPS from WDLPS with non-lipogenic areas, also known as cellular WDLPS. For consistency in diagnosis and research, only WD/DDLPS with≥5 mitoses/10 HPFs should be considered DDLPS.
    MeSH term(s) Humans ; Mitotic Index ; Liposarcoma/pathology ; Lipoma/pathology ; Mitosis
    Language English
    Publishing date 2023-04-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 752964-8
    ISSN 1532-0979 ; 0147-5185
    ISSN (online) 1532-0979
    ISSN 0147-5185
    DOI 10.1097/PAS.0000000000002037
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues.

    Liou, Sofia S / Memarzadeh, Sanaz / Dry, Sarah M / Graham, Rondell P / Moatamed, Neda A

    Autopsy & case reports

    2021  Volume 11, Page(s) e2021322

    Abstract: Only 14 cases of extraskeletal myxoid chondrosarcoma (EMC) of the vulva have been documented in the literature. We report a case of a 63-year-old woman with EMC of the vulva confirmed by ... ...

    Abstract Only 14 cases of extraskeletal myxoid chondrosarcoma (EMC) of the vulva have been documented in the literature. We report a case of a 63-year-old woman with EMC of the vulva confirmed by both
    Language English
    Publishing date 2021-08-20
    Publishing country Brazil
    Document type Case Reports
    ZDB-ID 2815488-5
    ISSN 2236-1960
    ISSN 2236-1960
    DOI 10.4322/acr.2021.322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Diagnostically Challenging Epithelioid Soft Tissue Tumors.

    James, Aaron W / Dry, Sarah M

    Surgical pathology clinics

    2015  Volume 8, Issue 3, Page(s) 309–329

    Abstract: In this article, we focus on the histologic features, differential diagnosis, and potential pitfalls in the diagnosis of epithelioid sarcoma, alveolar soft part sarcoma, clear-cell sarcoma, ossifying fibromyxoid tumor, and malignant extrarenal rhabdoid ... ...

    Abstract In this article, we focus on the histologic features, differential diagnosis, and potential pitfalls in the diagnosis of epithelioid sarcoma, alveolar soft part sarcoma, clear-cell sarcoma, ossifying fibromyxoid tumor, and malignant extrarenal rhabdoid tumor. Numerous other soft tissue tumors also may have epithelioid variants or epithelioid features. Examples include epithelioid angiosarcoma, epithelioid malignant peripheral nerve sheath tumor, epithelioid gastrointestinal stromal tumor, and perivascular epithelioid cell tumor, among others.
    MeSH term(s) Diagnosis, Differential ; Fibroma, Ossifying/diagnosis ; Fibroma, Ossifying/pathology ; Humans ; Prognosis ; Rhabdoid Tumor/diagnosis ; Rhabdoid Tumor/pathology ; Sarcoma/diagnosis ; Sarcoma/pathology ; Sarcoma, Clear Cell/diagnosis ; Sarcoma, Clear Cell/pathology ; Soft Tissue Neoplasms/diagnosis ; Soft Tissue Neoplasms/pathology
    Language English
    Publishing date 2015-09
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1875-9157
    ISSN (online) 1875-9157
    DOI 10.1016/j.path.2015.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Inhibition of HMGB1/RAGE Signaling Reduces the Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Mice.

    Gkouveris, Ioannis / Hadaya, Danny / Elzakra, Naseim / Soundia, Akrivoula / Bezouglaia, Olga / Dry, Sarah M / Pirih, Flavia / Aghaloo, Tara / Tetradis, Sotirios

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

    2022  Volume 37, Issue 9, Page(s) 1775–1786

    Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of antiresorptive or antiangiogenic medications, used in the treatment of bone malignancy or osteoporosis. Bone necrosis, mainly represented by osteocytic death, is always ... ...

    Abstract Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of antiresorptive or antiangiogenic medications, used in the treatment of bone malignancy or osteoporosis. Bone necrosis, mainly represented by osteocytic death, is always present in MRONJ sites; however, the role of osteocyte death in MRONJ pathogenesis is unknown. High mobility group box 1 (HMGB1) is a non-histone nucleoprotein that in its acetylated form accumulates in the cytoplasm, whereas non-acetylated HMGB1 localizes in the nucleus. SIRT1 deacetylase regulates cellular localization of HMGB1. Interestingly, HMGB1 is released during cell necrosis and promotes inflammation through signaling cascades, including activation of the RAGE receptor. Here, we utilized a well-established mouse MRONJ model that utilizes ligature-induced experimental periodontitis (EP) and treatment with either vehicle or zolendronic acid (ZA). Initially, we evaluated HMGB1-SIRT1 expression in osteocytes at 1, 2, and 4 weeks of treatment. Significantly increased cytoplasmic and perilacunar HMGB1 expression was observed at EP sites of ZA versus vehicle (Veh) animals at all time points. SIRT1 colocalized with cytoplasmic HMGB1 and presented a statistically significant increased expression at the EP sites of ZA animals for all time points. RAGE expression was significantly higher in the submucosal tissues EP sites of ZA animals compared with those in vehicle group. To explore the significance of increased cytoplasmic and extracellular HMGB1 and increased RAGE expression in MRONJ pathogenesis, we used pharmacologic inhibitors of these molecules. Combined HMGB1/RAGE inhibition resulted in lower MRONJ incidence with statistically significant decrease in osteonecrotic areas and bone exposure versus non-inhibitor treated ZA animals. Together, our data point to the role of HMGB1 as a central alarmin, overexpressed at early phase of MRONJ pathogenesis during osteocytic death. Moreover, HMGB1-RAGE pathway may represent a new promising therapeutic target in patients at high risk of MRONJ. © 2022 American Society for Bone and Mineral Research (ASBMR).
    MeSH term(s) Animals ; Bisphosphonate-Associated Osteonecrosis of the Jaw/drug therapy ; Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology ; Bone Density Conservation Agents/adverse effects ; Diphosphonates/adverse effects ; HMGB1 Protein/adverse effects ; HMGB1 Protein/metabolism ; Incidence ; Mice ; Osteonecrosis/chemically induced ; Osteonecrosis/drug therapy ; Osteoporosis/chemically induced ; Periodontitis ; Sirtuin 1
    Chemical Substances Bone Density Conservation Agents ; Diphosphonates ; HMGB1 Protein ; Sirtuin 1 (EC 3.5.1.-)
    Language English
    Publishing date 2022-07-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 632783-7
    ISSN 1523-4681 ; 0884-0431
    ISSN (online) 1523-4681
    ISSN 0884-0431
    DOI 10.1002/jbmr.4637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.

    Klingbeil, Kyle D / Tang, Jack Pengfei / Graham, Danielle S / Lofftus, Serena Y / Jaiswal, Amit Kumar / Lin, Tasha L / Frias, Chris / Chen, Lucia Y / Nakasaki, Manando / Dry, Sarah M / Crompton, Joseph G / Eilber, Fritz C / Rao, Dinesh S / Kalbasi, Anusha / Kadera, Brian E

    Cancers

    2023  Volume 15, Issue 18

    Abstract: Background: Although IGF2BP3 has been implicated in tumorigenesis and poor outcomes in multiple cancers, its role in soft-tissue sarcoma (STS) remains unknown. Preliminary data have suggested an association with IGF2BP3 expression among patients with ... ...

    Abstract Background: Although IGF2BP3 has been implicated in tumorigenesis and poor outcomes in multiple cancers, its role in soft-tissue sarcoma (STS) remains unknown. Preliminary data have suggested an association with IGF2BP3 expression among patients with well-differentiated/dedifferentiated liposarcoma (WD/DD LPS), a disease where molecular risk stratification is lacking.
    Methods: We examined the survival associations of IGF2BP3 via univariate and multivariate Cox regression in three unique datasets: (1) the Cancer Genome Atlas (TCGA), (2) an in-house gene microarray, and (3) an in-house tissue microarray (TMA). A fourth dataset, representing an independent in-house TMA, was used for validation.
    Results: Within the TCGA dataset, IGF2BP3 expression was a poor prognostic factor uniquely in DD LPS (OS 1.6 vs. 5.0 years,
    Conclusion: IGF2BP3 is highly expressed in a subset of WD/DD LPS. Across independent datasets, IGF2BP3 is also a biomarker of disease progression and worse survival.
    Language English
    Publishing date 2023-09-09
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15184489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Fibroblast Activation Protein Expression in Sarcomas.

    Crane, Jacquelyn N / Graham, Danielle S / Mona, Christine E / Nelson, Scott D / Samiei, Alireza / Dawson, David W / Dry, Sarah M / Masri, Marwan G / Crompton, Joseph G / Benz, Matthias R / Czernin, Johannes / Eilber, Fritz C / Graeber, Thomas G / Calais, Jeremie / Federman, Noah C

    Sarcoma

    2023  Volume 2023, Page(s) 2480493

    Abstract: Objectives: Fibroblast activation protein alpha (FAP) is highly expressed by cancer-associated fibroblasts in multiple epithelial cancers. The aim of this study was to characterize FAP expression in sarcomas to explore its potential utility as a ... ...

    Abstract Objectives: Fibroblast activation protein alpha (FAP) is highly expressed by cancer-associated fibroblasts in multiple epithelial cancers. The aim of this study was to characterize FAP expression in sarcomas to explore its potential utility as a diagnostic and therapeutic target and prognostic biomarker in sarcomas.
    Methods: Available tissue samples from patients with bone or soft tissue tumors were identified at the University of California, Los Angeles. FAP expression was evaluated via immunohistochemistry (IHC) in tumor samples (
    Results: The majority of tumor samples had FAP IHC intensity scores ≥2 and density scores ≥25% for stromal cells (77.7%) and tumor cells (50.7%). All desmoid fibromatosis, myxofibrosarcoma, solitary fibrous tumor, and undifferentiated pleomorphic sarcoma samples had medium or high FAP overall scores. Sarcomas were among cancer types with the highest mean FAP expression by RNA sequencing. There was no significant difference in OS in patients with sarcoma with low versus high FAP expression.
    Conclusion: The majority of the sarcoma samples showed FAP expression by both stromal and tumor/nonstromal cells. Further investigation of FAP as a potential diagnostic and therapeutic target in sarcomas is warranted.
    Language English
    Publishing date 2023-06-09
    Publishing country Egypt
    Document type Journal Article
    ZDB-ID 1338527-6
    ISSN 1357-714X
    ISSN 1357-714X
    DOI 10.1155/2023/2480493
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease.

    Hadaya, Danny / Soundia, Akrivoula / Gkouveris, Ioannis / Dry, Sarah M / Aghaloo, Tara L / Tetradis, Sotirios

    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons

    2018  Volume 77, Issue 1, Page(s) 71–86

    Abstract: Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe side effect of antiresorptive medications. Most animal models use tooth extraction as an instigating local factor to induce MRONJ, with varied results. However, these ... ...

    Abstract Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe side effect of antiresorptive medications. Most animal models use tooth extraction as an instigating local factor to induce MRONJ, with varied results. However, these teeth are healthy and absent of dental disease, a rare finding that does not reflect clinical practices. The authors hypothesized that extraction of teeth with periapical inflammation would lead to MRONJ in rats treated with high-dose bisphosphonates.
    Materials and methods: Rats were pretreated with zoledronic acid (ZA) for 1 week. Pulp exposure (PE) was established by exposing the pulpal chamber of the first and second molars. Experimental periapical disease (EPD) was induced by PE and bacterial inoculation into pulp chambers of the first and second mandibular molars. The mandibular molars were extracted 4 weeks after PE or EPD, and animals were euthanized 4 weeks after tooth extraction. Extraction sockets were assessed clinically, radiographically, and histologically.
    Results: Clinically, radiographically, and histologically, socket healing was observed in all vehicle-treated animals and in ZA-treated animals after extraction of healthy teeth or teeth with PE. In contrast, bone exposure, lack of socket healing, and osteonecrosis were present in most ZA-treated animals after extraction of teeth with EPD. Bacterial presence was noted in areas of osteonecrotic alveolar bone.
    Conclusion: These data support a synergistic contribution of severe dental disease and tooth extraction to MRONJ pathogenesis. Importantly, this model is amenable to manipulation of methodologic conditions for the dissection of parameters involved in MRONJ pathogenesis.
    MeSH term(s) Animals ; Bisphosphonate-Associated Osteonecrosis of the Jaw ; Bone Density Conservation Agents ; Diphosphonates ; Male ; Periapical Diseases ; Rats ; Rats, Wistar ; Tooth Extraction
    Chemical Substances Bone Density Conservation Agents ; Diphosphonates
    Language English
    Publishing date 2018-08-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 392404-x
    ISSN 1531-5053 ; 0278-2391
    ISSN (online) 1531-5053
    ISSN 0278-2391
    DOI 10.1016/j.joms.2018.08.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top